Company / Profit Margin
Intellia Therapeutics, Inc. Profit Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
-609.8%
FY2025
5-year range
-1326.5% / -609.8%
FY2021-FY2025
Trend
+32.0%
vs FY2024
Sector context
#147 of 150
Health Care
What the data says
Among 150 Health Care companies, Intellia Therapeutics, Inc. is in the bottom 2% for profit margin. Profit Margin has fluctuated over the past 9 years, ranging from -1326.5% in FY2023 to -192.0% in FY2016.
Based on SEC 10-K filings.
-609.8% in FY2025 with a 5-year CAGR of -378.4%.
Improved from -1326.5% to -609.8% over the past 2 years.
Health Care sector context is included.
Profit Margin over time
Growth rates
- 3-Year Change
- +299.9pp
- 5-Year Change
- -378.4pp
- 10-Year Change
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 150This company -609.8% Sector average -263.0%
▼
-131.9% below sector average
Key checks
Key Insights
- In FY2025, profit margin increased 32.0% year-over-year.
- Currently 346.9pp below the Health Care sector average.
- Peak profit margin was recorded in FY2016.
- Lowest profit margin in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -609.8% | +32.0% |
| FY2024 | -896.8% | +32.4% |
| FY2023 | -1326.5% | -45.8% |
| FY2022 | -909.8% | -12.3% |
| FY2021 | -810.5% | -250.2% |
| FY2020 | -231.5% | +79.0% |
| FY2019 | -1100.1% | -292.3% |
| FY2018 | -280.4% | - |
| FY2017 | - | - |
| FY2016 | -192.0% | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026